Interleukin-33 inhibitors - Pipeline Insight, 2024

This “Interleukin-33 inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Interleukin-33 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Interleukin-33 inhibitors Understanding

Interleukin-33 inhibitors: Overview

IL-33 belongs to the IL-1 family of cytokines. IL-33 is a novel cytokine that signals through the ST2 surface receptor. IL-33 receptor has a single chain, which is also related to the IL-1 receptor (interleukin-1 receptor-like 1, IL-1RL1). Signal transduction upon ligand binding involves the Toll-like receptor (TIR) domain of the receptor chain and resembles that of IL-1 and IL-18, and TLRs. IL-33 exhibits diverse immune regulatory functions during the various phases of different diseases. IL-33 likely functions as a disease sensitizer and plays pathological roles in inflamed tissues in allergic disorders that involve hyperreactive immune responses. In contrast, IL-33 also mediates tissue-protective functions during the recovery phase following tissue injury, which involves activation of tissue-reparative M2 macrophages, ILC2s, and Tregs. IL-33 could be used against inflammation caused by Th1 response, and antagonists perhaps might be developed as anti-allergic compounds. Targeting the IL-33-ST2 axis using monoclonal antibodies (or small-molecule inhibitors) could prove to be an effective strategy against COVID-19 virus. The combination of IL-33 blockade with other therapeutics could be an option for the efficacious treatment of inflammatory diseases.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-33 inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin-33 inhibitors.

Interleukin-33 inhibitors Emerging Drugs Chapters

This segment of the Interleukin-33 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin-33 inhibitors Emerging Drugs

MEDI3506: Astra Zeneca MEDI3506 is an IL-33 (interleukin-33) inhibiting monoclonal antibody being developed by AstraZeneca. The drug is currently in Phase II clinical studies for the treatment of COPD, atopic dermatitis, asthma, COVID-19 infection, and diabetickidneydisease.

Itepekimab: Regeneron Pharmaceuticals/Sanofi Itepekimab (REGN3500) is a fully-human monoclonal antibody that inhibits interleukin-33. The drug is being studied in Phase III trials for asthma, chronic obstructive pulmonary disease. REGN3500 was invented using Regeneron's proprietary VelocImmune technology that yields optimized fully-human antibodies, and is being developed jointly by Regeneron and Sanofi as part of a global collaborationagreement.

Interleukin-33 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin-33 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Interleukin-33 inhibitors

There are approx. 7+ key companies which are developing the Interleukin-33 inhibitors. The companies which have their Interleukin-33 inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals/Sanofi.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Interleukin-33 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin-33 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin-33 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-33 inhibitors drugs.

Interleukin-33 inhibitors Report Insights

• Interleukin-33 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Interleukin-33 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Interleukin-33 inhibitors drugs?
• How many Interleukin-33 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Interleukin-33 inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Interleukin-33 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interleukin-33 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Regeneron Pharmaceuticals
• Sanofi
• Genentech
• Cantargia

Key Products

• MEDI3506
• Itepekimab
• Astegolimab
• CAN-10